Click Here for 5% Off Your First Aladdin Purchase!

Vincamine - 98%, high purity , CAS No.1617-90-9, Allosteric modulator of M 1 receptor;Allosteric modulator of M 2 receptor;Allosteric modulator of M 3 receptor;Allosteric modulator of M 4 receptor

  • Moligand™
  • ≥98%
Item Number
V107385
Grouped product items
SKUSizeAvailabilityPrice Qty
V107385-250mg
250mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$39.90
V107385-1g
1g
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$79.90
V107385-5g
5g
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$266.90
V107385-25g
25g
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,059.90

Basic Description

SynonymsHMS2095H04 | C09251 | DTXSID9040134 | Methyl vincaminate | Oxybral | Tox21_111342_1 | Tripervan | Vincamina [DCIT] | VINCAMINE [MART.] | Anasclerol (base) | Equipur | KS-5179 | Vincamina | Cetal retard | HMS3712H04 | methyl (15S,17S,19S)-15-ethyl-17-hydro
Specifications & PurityMoligand™, ≥98%
Storage TempStore at 2-8°C
Shipped InWet ice
GradeMoligand™
Action TypeALLOSTERIC MODULATOR
Mechanism of actionAllosteric modulator of M 1 receptor;Allosteric modulator of M 2 receptor;Allosteric modulator of M 3 receptor;Allosteric modulator of M 4 receptor
Product Description

Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation. Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research.

Product Properties

ALogP2.9

Associated Targets

CXCR4 Tclin C-X-C chemokine receptor type 4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CNR1 Tclin Cannabinoid receptor 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CNR2 Tchem Cannabinoid receptor 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD1 Tclin D(1A) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD2 Tclin D(2) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ESR1 Tclin Estrogen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GABRA1 Tclin Gamma-aminobutyric acid receptor subunit alpha-1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CCR8 Tchem C-C chemokine receptor type 8 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PRLHR Tchem Prolactin-releasing peptide receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FPR1 Tchem fMet-Leu-Phe receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HRH3 Tclin Histamine H3 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HRH1 Tclin Histamine H1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B1 Tchem Solute carrier organic anion transporter family member 1B1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B3 Tchem Solute carrier organic anion transporter family member 1B3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A2 Tclin Sodium-dependent noradrenaline transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A3 Tclin Sodium-dependent dopamine transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A4 Tclin Sodium-dependent serotonin transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PGR Tclin Progesterone receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE3A Tclin cGMP-inhibited 3',5'-cyclic phosphodiesterase A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS1 Tclin Prostaglandin G/H synthase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE4A Tclin cAMP-specific 3',5'-cyclic phosphodiesterase 4A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGIR Tclin Prostacyclin receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD3 Tclin D(3) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KDR Tclin Vascular endothelial growth factor receptor 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM3 Tclin Muscarinic acetylcholine receptor M3 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM4 Tclin Muscarinic acetylcholine receptor M4 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM2 Tclin Muscarinic acetylcholine receptor M2 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ACHE Tclin Acetylcholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM1 Tclin Muscarinic acetylcholine receptor M1 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2A Tclin Alpha-2A adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA1A Tclin Alpha-1A adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AR Tclin Androgen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GNAS Tbio Protein ALEX 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAOA Tclin Amine oxidase [flavin-containing] A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR1A Tclin 5-hydroxytryptamine receptor 1A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA3 Tchem Adenosine receptor A3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2B Tclin 5-hydroxytryptamine receptor 2B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TBXA2R Tclin Thromboxane A2 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

F2 Tclin Prothrombin 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ATAD5 Tbio ATPase family AAA domain-containing protein 5 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BCHE Tclin Cholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GPR119 Tclin Glucose-dependent insulinotropic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HCRTR2 Tclin Orexin receptor type 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRM1 Tclin Mu-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NPSR1 Tchem Neuropeptide S receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
INCHI InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1
InChi Key RXPRRQLKFXBCSJ-GIVPXCGWSA-N
Canonical SMILES CCC12CCCN3C1C4=C(CC3)C5=CC=CC=C5N4C(C2)(C(=O)OC)O
Isomeric SMILES CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@](C2)(C(=O)OC)O
WGK Germany 3
RTECS YY8575000
PubChem CID 15376
Molecular Weight 354.44
Beilstein 25(3/4)1252

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

6 results found

Lot NumberCertificate TypeDateItem
D2402505Certificate of AnalysisMar 09, 2024 V107385
D2402517Certificate of AnalysisMar 09, 2024 V107385
D2402518Certificate of AnalysisMar 09, 2024 V107385
D2402519Certificate of AnalysisMar 09, 2024 V107385
C1813119Certificate of AnalysisJan 27, 2022 V107385
C1813120Certificate of AnalysisJan 27, 2022 V107385

Chemical and Physical Properties

Specific Rotation[α]43° (C=1,Pyridine)
Melt Point(°C)232°C

Safety and Hazards(GHS)

Pictogram(s) GHS07
Signal Warning
Hazard Statements

H302:Harmful if swallowed

Precautionary Statements

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P270:Do not eat, drink or smoke when using this product.

P330:Rinse mouth.

P301+P317:IF SWALLOWED: Get medical help.

WGK Germany 3
RTECS YY8575000
Merck Index 9983

Related Documents

References

1. L Bezin,D Marcel,S Desgeorges,J F Pujol,D Weissmann.  (2000-04-14)  Singular subsets of locus coeruleus neurons may recover tyrosine hydroxylase phenotype transiently expressed during development..  Brain research. Molecular brain research,  76  ((2)): (275-281).  [PMID:10762702]
2. S Caccamese,G Principato.  (2000-10-24)  Separation of the four pairs of enantiomers of vincamine alkaloids by enantioselective high-performance liquid chromatography..  Journal of chromatography. A,  893  ((1)): (47-54).  [PMID:11043586]
3. S Caccamese,G Principato,R Jokela,A Tolvanen,D Din Belle.  (2001-12-18)  Chiral HPLC separation and CD spectra of the enantiomers of the alkaloid tacamonine and related compounds..  Chirality,  13  ((10)): (691-693).  [PMID:11746802]
4. Y Kitazawa.  (2002-01-23)  [Open-angle glaucoma clinical presentation and management]..  Nippon Ganka Gakkai zasshi,  105  ((12)): (828-842).  [PMID:11802456]
5. Ying-Ping Juan,Tung-Hu Tsai.  (2005-09-01)  Measurement and pharmacokinetics of vincamine in rat blood and brain using microdialysis..  Journal of chromatography. A,  1088  ((1-2)): (146-151).  [PMID:16130744]
6. Adám Vas,Balázs Gulyás.  (2005-09-15)  Eburnamine derivatives and the brain..  Medicinal research reviews,  25  ((6)): (737-757).  [PMID:16158388]
7. Li Di,Edward H Kerns,Hong Chen,Susan L Petusky.  (2005-10-20)  Development and application of an automated solution stability assay for drug discovery..  Journal of biomolecular screening,  11  ((1)): (40-47).  [PMID:16234336]
8. Dylan B England,Albert Padwa.  (2007-07-31)  Synthesis of (+/-)-3H-epivincamine via a Rh(II)-triggered cyclization/cycloaddition cascade..  Organic letters,  ((17)): (3249-3252).  [PMID:17658832]
9. Amr Mohamed Beltagi.  (2008-12-02)  Development and validation of an adsorptive stripping voltammetric method for the quantification of vincamine in its formulations and human serum using a Nujol-based carbon paste electrode..  Chemical & pharmaceutical bulletin,  56  ((12)): (1651-1657).  [PMID:19043234]
10. Thomas Sycha,Clemens Vass,Oliver Findl,Peter Bauer,Ilse Groke,Leopold Schmetterer,Hans-Georg Eichler.  (2010-02-19)  WITHDRAWN: Interventions for normal tension glaucoma..  The Cochrane database of systematic reviews,    ((2)(2)): (CD002222-CD002222).  [PMID:20166063]
11. Koichiro Koyama,Yusuke Hirasawa,Takahiro Hosoya,Teh Chin Hoe,Kit-Lam Chan,Hiroshi Morita.  (2010-06-26)  Alpneumines A-H, new anti-melanogenic indole alkaloids from Alstonia pneumatophora..  Bioorganic & medicinal chemistry,  18  ((12)): (4415-4421).  [PMID:20576577]
12. Hong Yin,Yu-Hong Sun.  (2011-02-15)  Vincamine-producing endophytic fungus isolated from Vinca minor..  Phytomedicine : international journal of phytotherapy and phytopharmacology,  18  ((8-9)): (802-805).  [PMID:21315568]
13. Entai Hou,Yingjuan Wang,Duowei Li,Na Li,Hongdong Chen,Huaiyu Bu.  (2011-07-19)  [Tissue culture of Vinca minor and determination of vincamine]..  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,  36  ((7)): (823-827).  [PMID:21761716]
14. Dritan Hasa,Beatrice Perissutti,Cinzia Cepek,Sunil Bhardwaj,Elvio Carlino,Mario Grassi,Sergio Invernizzi,Dario Voinovich.  (2012-11-29)  Drug salt formation via mechanochemistry: the case study of vincamine..  Molecular pharmaceutics,  10  ((1)): (211-224).  [PMID:23186380]
15. Amir Akhgari,Into Laakso,Tuulikki Seppänen-Laakso,Teijo Yrjönen,Heikki Vuorela,Kirsi-Marja Oksman-Caldentey,Heiko Rischer.  (2015-06-23)  Determination of terpenoid indole alkaloids in hairy roots of Rhazya stricta (Apocynaceae) by GC-MS..  Phytochemical analysis : PCA,  26  ((5)): (331-338).  [PMID:26095837]
16. Takashi Matsumoto,Yousuke Matsubara,Yasuharu Mizuhara,Kyoji Sekiguchi,Junichi Koseki,Kazuaki Tsuchiya,Hiroaki Nishimura,Junko Watanabe,Atsushi Kaneko,Kazuya Maemura,Tomohisa Hattori,Yoshio Kase.  (2015-10-06)  Plasma Pharmacokinetics of Polyphenols in a Traditional Japanese Medicine, Jumihaidokuto, Which Suppresses Propionibacterium acnes-Induced Dermatitis in Rats..  Molecules (Basel, Switzerland),  20  ((10)): (18031-18046).  [PMID:26437394]
17. L Vereczkey.  (1985-04-01)  Pharmacokinetics and metabolism of vincamine and related compounds..  European journal of drug metabolism and pharmacokinetics,  10  ((2)): (89-103).  [PMID:3899662]
18. Mazák Károly,József Vámos,András Nemes,Akos Rácz,Béla Noszál.  (2003-07-02)  Lipophilicity of vinpocetine and related compounds characterized by reversed-phase thin-layer chromatography..  Journal of chromatography. A,  996  ((1-2)): (195-203).  [PMID:12830921]
19. T Sycha,C Vass,O Findl,P Bauer,I Groke,L Schmetterer,H Eichler.  (2003-10-30)  Interventions for normal tension glaucoma..  The Cochrane database of systematic reviews,  (4)  ((4)): (CD002222-CD002222).  [PMID:14583947]
20. Laurent Bezin,Catherine Ortemann,Michaël Ogier,Bernadette Astier,Jean-François Pujol,Bernard Renaud,Laura Lambas-Señas.  (2004-11-30)  Enhanced tail pinch-induced activation of catecholamine metabolism in the pericerulean area of RU 24722-treated rats..  Brain research,  1030  ((1)): (1-10).  [PMID:15567332]
21. Mostafa A M Shehata,Mohammad A El Sayed,Mohammad F El Tarras,Mohammad G El Bardicy.  (2005-05-24)  Stability-indicating methods for determination of vincamine in presence of its degradation product..  Journal of pharmaceutical and biomedical analysis,  38  ((1)): (72-78).  [PMID:15907622]
22. Mohammad G El-Bardicy,Hayam M Lotfy,Mohammad A El-Sayed,Mohammad F El-Tarras.  (2008-05-15)  Smart stability-indicating spectrophotometric methods for determination of binary mixtures without prior separation..  Journal of AOAC International,  91  ((2)): (299-310).  [PMID:18476341]
23. Yasser Shaker Ibrahim El-Saharty.  (2008-05-15)  Simultaneous determination of piracetam and vincamine by spectrophotometric and high-performance liquid chromatographic methods..  Journal of AOAC International,  91  ((2)): (311-321).  [PMID:18476342]
24. Abdel-Hasseb A Fayed.  (2009-11-11)  Brain trace element concentration of rats treated with the plant alkaloid, vincamine..  Biological trace element research,  136  ((3)): (314-319).  [PMID:19902161]
25. K Cambon,R Dos-Santos Coura,L Groc,A Carbon,D Weissmann,J P Changeux,J F Pujol,S Granon.  (2010-10-07)  Aggressive behavior during social interaction in mice is controlled by the modulation of tyrosine hydroxylase expression in the prefrontal cortex..  Neuroscience,  171  ((3)): (840-851).  [PMID:20923695]
26. Paul E Polak,Sergey Kalinin,David Braun,Anthony Sharp,Shao X Lin,Douglas L Feinstein.  (2012-02-01)  The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: effects on the Locus coeruleus..  Journal of neurochemistry,  121  ((2)): (206-216).  [PMID:22288774]

Solution Calculators